In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

New insights on cardiometabolic risk management

CRT Plenary Meeting - 12 May 2022 - Lisbon 09:00 - 16:00 WEST

12/05/2022 10:00 12/05/2022 17:00 Europe/Paris New insights on cardiometabolic risk management

Access event page

contact@escardio.org DD/MM/YYYY
In-person
event

Summary

Chairpersons: Prof. Francesco Cosentino (ESC), Dr. Subodh Verma (Toronto, CA), Dr Philip Ambery (AstraZeneca), Dr Martin van Eickels (Bayer), Dr Marianne Bach-Treppendahl (Novo Nordisk)



Replay session 1

Replay session 2

 

Replay session 3

Replay session 4

 

Replay session 5

Replay: Closing Lecture 

 

Objectives of the meeting

A significant number of patients with cardiovascular disease (CVD) have concomitant metabolic comorbidities which play a causal and/or permissive role in adverse prognosis.

  • The primary objective of the meeting is to improve the recognition and treatment of CVD in patients with multiple metabolic comorbidities. 
  • The meeting also aims to assess potential mechanism-based approaches to intervention across multiple disorders.

Questions to be addressed

  • How can we improve recognition and treatment of cardiovascular disease in patients with obesity, insulin resistance, NASH, and renal disease when associated with metabolic comorbidity?
  • How can we improve the recognition and treatment of metabolic and renal disease in patients at the cardiology clinic?
  • Are there mechanism-based approaches that can address multiple pathologies across diseases?
  • What is important to patients with cardiovascular and metabolic diseases? How can we meet their needs?
  • Why may COVID-19 be particularly damaging for patients with cardiovascular and metabolic disease?
  • Can we move from broad regulatory definitions to better targeting patients with multiple comorbidities?

Programme

 


12 May 

09:00 – 16:00 Local time (Western European Time)

09:00 – 09:10

Welcome – Introduction and objectives of the meeting                                  

Chairpersons

09:10 – 09:40

Session I - Common soil and common targets for CKD, NASH and HF?

10 min presentations

The epidemiological basis                             

Prof. Philip Newsome (Birmingham) - via Zoom

What are the biological underpinnings of the relationship between metabolic and cardiovascular disease?

Prof. Faiez Zannad (Nancy)

What are the clinical and practical implications for physicians as it relates to this interface?

Prof. Per-Henrik Groop (Helsinki)

09:40 – 10:00

Discussion

10:00 - 10:30

Session II – Unravelling the relationships between obesity and CKD in patients with CV disease

10 min presentations

Epidemiology and natural history of this relationship               

Prof. Paola Fioretto (Padova)

Obesity and HFpEF – common soil?                            

Prof. Lars Lund (Stockholm) - via Zoom

Obesity paradox                                                                                   

Prof.  Stefan Anker (Berlin)

10:30 - 10:45

Discussion

10:45 - 11:05

Break

11:05 - 11:35

Session III - COVID-19: a new threat at the cross-roads between cardiovascular and metabolic diseases

10 min presentations

How metabolic derangements affect the incidence and natural history of COVID-19

Prof. Naveed Sattar (Glasgow) - via Zoom

CV derangement in COVID-19                                                    

Prof. Scott S. Solomon (Boston)

What are the practical management implications of cardiometabolic disease in patients with COVID-19

Prof. Kamlesh Khunti (Leicester)

11:35 - 12:00

Discussion

12:00 - 12:15

Session IV - A patient’s perspective on heart failure, renal disease and diabetes.

  • Canadian patient (video)
  • ESC patient - Mr Paul McGreavy (UK) - 10 min presentation

12:15 - 12:45

Discussion

12:45 - 13:45

Lunch

13:45 - 14:15

Session V - Mechanisms of chronic cardiometabolic diseases and opportunities for intervention.

10 min presentations

Sex differences in cardiometabolic risk and opportunities for intervention
Dr. Carolyn Sp Lam (Singapore) - via Zoom

Circulating biomarkers and their utility in cardiometabolic disease

Prof. Andreas M. Zeiher (Frankfurt)

Reversal of Pro-vascular Regenerative Cell Exhaustion in Diabetes and Obesity  

Dr. David Hess (Toronto)

14:15 - 14:35

Discussion

14:35 - 14:55

Lecture – Health and economics consequences of obesity
Prof. Michele Cecchini (OECD)

Questions to be addressed

  • What have we learnt from GBD study?
  • What do we need to do to stem the tide?

14:55 - 16:00

Panel discussion

16:00

Wrap-up – Next steps – A publication